Isolation and total synthesis of stolonines A-C, unique taurine amides from the Australian marine tunicate Cnemidocarpa stolonifera

Article abstract of DOI:10.3390/md13074556

Cnemidocarpa stolonifera is an underexplored marine tunicate that only occurs on the tropical to subtropical East Coast of Australia, with only two pyridoacridine compounds reported previously. Qualitative analysis of the lead-like enhanced fractions of C. stolonifera by LC-MS dual electrospray ionization coupled with PDA and ELSD detectors led to the identification of three new natural products, stolonines A-C (1-3), belonging to the taurine amide structure class. Structures of the new compounds were determined by NMR and MS analyses and later verified by total synthesis. This is the first time that the conjugates of taurine with 3-indoleglyoxylic acid, quinoline-2-carboxylic acid and β-carboline-3-carboxylic acid present in stolonines A-C (1-3), respectively, have been reported. An immunofluorescence assay on PC3 cells indicated that compounds 1 and 3 increased cell size, induced mitochondrial texture elongation, and caused apoptosis in PC3 cells.

Full text of DOI:10.3390/md13074556

Mar. Drugs 2015, 13, 4556-4575; doi:10.3390/md13074556
OPEN ACCESS
marine drugs
ISSN 1660-3397
www.mdpi.com/journal/marinedrugs
Article
Isolation and Total Synthesis of Stolonines A–C, Unique
Taurine Amides from the Australian Marine Tunicate
Cnemidocarpa stolonifera
Trong D. Tran 1, Ngoc B. Pham 1, Merrick Ekins 2, John N. A. Hooper 1,2 and
Ronald J. Quinn 1,*
1
Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland 4111, Australia;
E-Mails: trong.tran@griffithuni.edu.au (T.D.T.); n.pham@griffith.edu.au (N.B.P.);
john.hooper@qm.qld.gov.au (J.N.A.H.)
2
Queensland Museum, Brisbane, Queensland 4101, Australia;
E-Mail: merrick.ekins@qm.qld.gov.au
* Author to whom correspondence should be addressed; E-Mail: r.quinn@griffith.edu.au;
Tel.: +61-7-3735-6009; Fax: +61-7-3735-6001.
Academic Editor: Sylvia Urban
Received: 19 June 2015 / Accepted: 14 July 2015 / Published: 22 July 2015
Abstract: Cnemidocarpa stolonifera is an underexplored marine tunicate that only occurs
on the tropical to subtropical East Coast of Australia, with only two pyridoacridine
compounds reported previously. Qualitative analysis of the lead-like enhanced fractions of
C. stolonifera by LC-MS dual electrospray ionization coupled with PDA and ELSD
detectors led to the identification of three new natural products, stolonines A–C (1–3),
belonging to the taurine amide structure class. Structures of the new compounds were
determined by NMR and MS analyses and later verified by total synthesis. This is the first
time that the conjugates of taurine with 3-indoleglyoxylic acid, quinoline-2-carboxylic acid
and β-carboline-3-carboxylic acid present in stolonines A–C (1–3), respectively, have been
reported. An immunofluorescence assay on PC3 cells indicated that compounds 1 and 3
increased cell size, induced mitochondrial texture elongation, and caused apoptosis in
PC3 cells.
Keywords: Cnemidocarpa stolonifera; taurine amide; PC3 cell line; immunofluorescence
assay

Mar. Drugs 2015, 13
4557
1. Introduction
The exploration of marine secondary metabolites only began in the early 1950s [1] with the landmark
identification of the two nucleosides spongothymidine and spongouridine from the Caribbean marine
sponge Cryptotethia crypta [2,3]. Since then, marine natural product discovery has increased annually
and has accelerated over the last two decades [4]. By 2010 more than 15,000 new marine natural products
were discovered with 8368 new compounds recorded in a decade between 2001 and 2010 [5].
Approximately 75% of marine natural products were isolated from marine invertebrates [4] from which
sponges, tunicates, bryozoans or molluscs have provided the majority of the compounds involved in
clinical or preclinical trials [5]. It is expected that the discovery of marine natural products will provide
new and improved therapeutics for human illnesses, along with other innovative products for other
industrial activities (e.g., nutraceutics and biotechnology) [6].
To maximize the chance to discover new marine natural products, a library of fractions from rare or
restricted marine invertebrates was generated from the Nature Bank database [7]. Qualitative analysis of
lead-like enhanced fractions of samples in the selected library by LC-MS dual electrospray ionization
coupled with PDA and ELSD detectors [8–10] indicated that the marine tunicate Cnemidocarpa
stolonifera contained two different compound classes in two different fractions. The first class showed
strong MS signals in a positive mode and strong UV absorptions at 380 nm while the second one
displayed strong MS signals in a negative mode and strong UV absorptions at 280 nm. Mass-guided
isolation of the marine tunicate C. stolonifera extract led to the isolation of two known pyridoacridine
alkaloids, 11-hydroxyascididemin (4) and cnemidine A (5) [11], accounting for the first compound class.
For the second class of compounds, three new taurine amide derivatives, stolonines A–C (1–3),
were isolated.
Taurine is found at high concentration in mammalian plasma and tissues [12]. This compound has
been known to exhibit a large spectrum of physiological functions in the liver, kidney, heart, pancreas,
retina, and brain [13,14]. Its depletion is associated with several disease conditions such as diabetes,
Parkinson’s, Alzheimer’s, cardiovascular diseases, and neuronal damages in the retina [13]. So far,
81 taurine derivatives from natural sources have been reported of which 47 compounds are amides
produced between taurine with fatty acids, steroid acids or other aromatic acid residues [15].
The occurrence of the conjugates of taurine with 3-indoleglyoxylic acid, quinoline-2-carboxylic acid and
β-carboline-3-carboxylic acid present in stolonines A–C (1–3), respectively, has not been previously
reported. This paper describes the isolation, structure elucidation and total synthesis of stolonines A–C
(1–3) from the marine tunicate C. stolonifera. Cytotoxicity of 1–3 against human prostate cancer
PC3 cell line was evaluated and the result indicated that they were not active up to 20 μM. However, an
immunofluorescence assay on PC3 cells revealed that compounds 1 and 3 increased cell size, induced
mitochondrial texture elongation and caused apoptosis in PC3 cells.
2. Results and Discussion
The freeze-dried C. stolonifera tunicate was sequentially extracted with n-hexane, dichloromethane
(DCM), and methanol (MeOH). The DCM/MeOH extracts were then combined and chromatographed
using C18 bonded silica HPLC MeOH/H2O/0.1% trifluoroacetic acid (TFA) to yield three new alkaloids,

Mar. Drugs 2015, 13
4558
stolonines A–C (1–3) together with two known alkaloids, 11-hydroxyascididemin (4) and cnemidine A
(5) (Figure 1).
O
H
N
SO3H
O
N
H
N
N
1
O
HO
H
N
N
N
SO3H
R
O
2
4
5
R = H
R = CH3
O
SO3H
N
H
N
N
H
3
Figure 1. Structures of stolonines A-C (1–3), 11-hydroxyascididemin (4) and cnemidine A
(5) isolated from the tunicate C. stolonifera.
Stolonine A (1) was obtained as a white amorphous solid. The (−)-HRESIMS spectrum displayed a
molecular ion [M−H]− at m/z 295.0390, which was consistent with the molecular formula C12H12N2O5S.
1
The IR spectrum indicated the presence of an S=O stretching band at 1205 cm−1 [16]. A H NMR
spectrum of 1 showed two exchangeable protons (δH 12.20 and 8.78 ppm), five aromatic protons
(δH 8.82, 8.22, 7.52, 7.26 and 7.24 ppm) and two methylenes (δH 3.50 and 2.66 ppm). Further analysis
of the 13C NMR and gHSQCAD spectra indicated that the molecule contained two carbonyls (δC 181.6
and 162.7 ppm), eight aromatic carbons (δC 138.5, 136.2, 126.2, 123.3, 122.4, 121.3, 112.5 and 112.1 ppm)
and two methylenes (δC 49.8 and 35.5 ppm) (Table 1). J coupling constants of aromatic protons H-4 (δH
8.22, dd, 1.8, 7.2 Hz), H-5 (δH 7.24, dt, 1.8, 7.2 Hz), H-6 (δH 7.26, dt, 1.8, 7.2 Hz) and H-7
(δH 7.52, dd, 1.8, 7.2 Hz) and their COSY correlations were characteristic of a 1,2-disubstituted benzene
ring (a, Figure 2). A gCOSY spectrum displayed correlations from the exchangeable proton H-1 (δH
12.20, br.s) to H-2 (δH 8.82, d, 3.0 Hz) and also from H-11 (δH 3.50, dd, 6.0, 6.6 Hz) to the triplet
exchangeable proton H-10 (δH 8.78, t, 5.4 Hz) and H-12 (δH 2.66, t, 6.6 Hz) facilitating the establishment
of two other spin systems, –NH–CH= (b, Figure 2) and –NH–CH2–CH2– (c, Figure 2) respectively. The
aromatic carbon C-3 (δC 112.1 ppm) was attached to C-2 (δC 138.5 ppm) in the moiety b determined by
a HMBC correlation from H-2 to C-3. A HMBC correlation from H-2 to C-7a (δC 136.2 ppm) supported
the linkage from a to b at C-7a (Figure 2). Both protons H-10 and H-11 in the moiety c showed HMBC
correlations with a carbonyl carbon at δC 162.7 ppm suggesting the connection of this carbonyl to N-10
to form an amide bond (c, Figure 2). Two methylene signals at δH 3.50 and 2.66 ppm corresponding to
carbons C-11 (δC 35.5 ppm) and C-12 (δC 49.8 ppm) as well as the relatively downfield resonance of the
methylene C-12 were diagnostic of methylenes in a taurine moiety (c, Figure 2) [17–19].

Mar. Drugs 2015, 13
4559
a
Table 1. NMR data for 1 in DMSO-d6 .
Position
δC
δH (J in Hz)
12.20, br.s
gCOSY
gHMBCAD
1
2
2
1
138.5
112.1
126.2
121.3
122.4
123.3
112.5
136.2
181.6
162.7
8.82, d (3.0)
3, 3a, 7a
3
3a
4
8.22, dd (1.8, 7.2)
7.24, dt (1.8, 7.2)
7.26, dt (1.8, 7.2)
7.52, dd (1.8, 7.2)
5
6, 7a
3a, 7
4, 7a
3a, 5
5
4, 6
5, 7
6
6
7
7a
8
9
10
11
12
8.78, t (5.4)
3.50, dd (6.0, 6.6)
2.66, t (6.6)
11
10, 12
11
9
35.5
49.8
9, 12
11
a
1H NMR at 600 MHz referenced to residual DMSO solvent (δH 2.50 ppm) and 13C NMR at 150 MHz
referenced to residual DMSO solvent (δC 39.52 ppm).
3
10
4
H
12
3a
7a
5
6
N
SO3H
9
11
HMBC
2
N
H
1
O
7
a
c
b
Figure 2. Partial structures (a, b and c) of 1 and their key HMBC correlations.
No HMBC correlation from any proton to the carbonyl C-8 (δC 181.6 ppm) was observed when
HMBC experiments were performed and optimized with different JHC couplings. Therefore, two
different isomers 1-I and 1-II were conceivable from these data (Figure 3). Detailed HMBC analysis
showed that H-2 had a HMBC correlation with C-3a (δC 126.2 ppm). This suggested that 1 was favorable
to 1-I since the H-2 to C-3a correlation in 1-I was a three-bond coupling while the H-2 to
C-3a correlation in 1-II was a four-bond coupling (Figure 3).
O
O
O
4
H
4
3a
9
3
SO3H
N
3a
3
8
9
N
8
SO3H
H
HMBC
O
2
2
N
H
N
H
1-I
1-II
Figure 3. Two possible structures 1-I and 1-II of 1 (1-I and 1-II are possible structural
isomers of 1).
Density functional theory (DFT) NMR calculations together with the DP4 probability analysis, which
have recently emerged as powerful tools for the determination of structures that lack sufficient NMR
characterization or contain unusual constituents or connectivities [20–25], were employed to verify the

Mar. Drugs 2015, 13
4560
assigned structure for 1. Theoretical 1H and 13C chemical shifts were calculated at the mPW1PW91/6-
31G(d)//B3lyp/6-31G(d) levels. Calculated NMR data of 1-I and 1-II were then compared with the
experimental NMR data based on the corrected mean absolute error (CMAE) and the DP4 probability
(Computational Details, Experimental Section) to determine which of the isomers fit with the
13
1
experimental data. The results (Table 2) indicated that both C and H chemical shifts of the isomer
1-I showed lower CMAE compared to those of the isomer 1-II. Significant differences were observed
in DP4 probabilities. In particular, 1-I had 100% probability for 13C chemical shifts and 85.3%
probability for 1H chemical shifts while 1-II only occupied 0% for 13C chemical shifts and 14.7% for 1H
chemical shifts (Table 2). These probabilities indicated that the assignment of the isomer 1-I for 1 was
at a high level of confidence [20]. Therefore, the structure of 1 was suggested as the isomer 1-I.
1
Table 2. Comparison of experimental and calculated 13C and H chemical shifts for 1
in DMSO-d6.
1-I
1-II
1-I
1-II
δC
δH
Position
δC
δC
δC
δC
δH
δH
δH
δH
(Exp.)
(Exp.)
(Calc.) (Scaled) (Calc.) (Scaled)
(Calc.) (Scaled) (Calc.) (Scaled)
2
138.5
112.1
126.2
121.3
122.4
123.3
112.5
136.2
181.6
162.7
35.5
136.9
111.5
124.1
118.9
120.1
120.9
108.7
131.9
176.7
156.8
37.1
140.3
112.9
126.5
120.9
122.1
123.0
109.9
134.9
183.2
161.7
32.6
141.3
111.2
123.0
124.3
121.1
129.4
114.8
134.4
172.5
159.4
36.9
142.8
110.2
122.9
124.4
120.9
129.9
114.1
135.3
176.5
162.4
29.8
8.82
8.74
8.61
8.84
8.67
3
3a
4
8.22
7.24
7.26
7.52
8.62
7.63
7.59
7.55
8.48
7.40
7.36
7.31
8.40
7.63
8.00
7.53
8.19
7.35
7.76
7.24
5
6
7
7a
8
9
11
3.50
2.66
3.69
3.55
3.11
2.95
0.23
3.71
3.57
3.08
2.93
0.25
12
49.8
57.2
54.4
58.4
53.1
CMAE
DP4
1.5
3.1
100.0%
0.0%
85.3%
14.7%
Compound 1-I was synthesized by coupling 3-indoleglyoxylic acid (6) with taurine (Scheme 1) in
the presence of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI), N-hydroxybenzotriazole
(HOBt) and dimethylformamide (DMF) at room temperature (rt) for 21 h (64% yield) [26]. Both 1H and
13C NMR data of the synthetic 1-I completely matched those of the natural product 1 (Table 3)
confirming that 1-I was the structure of 1. Therefore, compound 1 was defined as a new alkaloid with a
trivial name stolonine A.
O
OH
a
1-I
O
N
H
6
Scheme 1. Synthesis of 1. (a) Taurine, EDCI, HOBt, DMF, rt, 21 h, 64%.

Mar. Drugs 2015, 13
4561
Table 3. 1H and 13C NMR chemical shifts of natural and synthetic products of 1–3 a.
1
2
3
Position
Natural Product a
Synthetic Product b
Natural Product a
Synthetic Product b
Natural Product a
Synthetic Product b
a
δC
δH (J in Hz)
12.20, br.s
δC
δH (J in Hz)
12.19, br.s
δC
δH (J in Hz)
δC
δH (J in Hz)
δC
δH (J in Hz)
δC
δH (J in Hz)
1
2
131.3
8.95, s
131.3
8.95, s
138.5
112.1
126.2
121.3
8.82, d (3.0)
138.5
112.1
126.2
121.3
8.82, d (3.0)
150.1
118.6
150.1
118.6
3
8.15, d (8.4)
8.55, d (8.4)
8.15, d (8.5)
8.55, d (8.5)
138.0
138.0
3a
4
8.22, dd (1.8, 7.2)
8.22, d (7.5)
137.8
129.2
137.8
129.2
114.0
128.9
120.7
122.3
120.3
129.2
8.93, s
114.1
129.0
120.7
122.3
120.3
129.2
8.93, s
4a
4b
5
122.4
123.3
112.5
136.2
181.6
7.24, dt (1.8, 7.2)
7.26, dt (1.8, 7.2)
7.52, dd (1.8, 7.2)
122.4
123.3
112.5
136.2
181.6
7.24, t (7.5)
7.26, t (7.5)
7.52, d (7.5)
128.7
128.0
130.4
8.08, d (7.8)
7.71, t (7.2, 7.8)
7.87, t (7.2, 7.8)
128.7
128.0
130.4
8.08, d (8.0)
7.71, t (8.0)
7.87, t (8.0)
8.39, d (7.8)
7.35, t (7.2, 7.8)
7.64, t (7.2, 7.8)
8.39, d (8.0)
6
7.35, t (7.5, 8.0)
7.64, t (7.5, 8.0)
7
7a
8
128.1
146.0
163.5
8.06, d (7.8)
128.1
146.0
163.5
8.06, d (8.0)
112.5
141.6
7.70, d (7.8)
12.11, s
112.5
141.6
7.70, d (8.0)
12.10, s
8a
9
162.7
162.7
9a
10
11
12
136.7
163.3
136.6
163.3
8.78, t (5.4)
3.50, dd (6.0, 6.6)
2.66, t (6.6)
8.78, t (5.4)
3.50, dd (6.0, 6.5)
2.66, t (6.5)
9.29, t (5.4)
3.65, dd (6.0, 6.6)
2.72, t (6.6)
9.29, t (5.0)
3.65, dd (5.5, 6.5)
2.72, t (6.5)
35.5
49.8
35.5
49.8
35.9
50.1
35.9
50.1
9.15, t (5.4)
9.15, t (5.5)
3.66, dd (5.5, 6.0)
2.72, t (6.0)
35.9
50.3
3.66, dd (5.4, 6.6)
35.9
50.3
13
2.72, t (6.6)
a
b
1H NMR at 600 MHz at 30 °C referenced to residual DMSO solvent (δH 2.50 ppm) and 13C NMR at 150 MHz at 30 °C referenced to residual DMSO solvent (δC 39.52 ppm); 1H NMR at 500 MHz at 30 °C
referenced to residual DMSO solvent (δH 2.50 ppm) and 13C NMR at 125 MHz at 30 °C referenced to residual DMSO solvent (δC 39.52 ppm).

Mar. Drugs 2015, 13
4562
Stolonine B (2) was purified as a white amorphous solid. A molecular ion [M − H]− at m/z 279.0441
1
in the (−)-HRESIMS spectrum indicated that 2 had a molecular formula C12H12N2O4S. A H NMR
spectrum of 2 displayed one exchangeable proton (δH 9.29 ppm), six aromatic protons (δH 8.55, 8.15,
8.08, 8.06, 7.87 and 7.71 ppm) and two methylenes (δH 3.65 and 2.72 ppm). 13C NMR combined with
gHSQCAD spectra indicated that 2 contained nine aromatic carbons including six tertiary carbons
(δC 137.8, 130.4, 128.7, 128.1, 128.0 and 118.6 ppm) and three quaternary carbons (δC 150.1, 146.0 and
129.2 ppm), one carbonyl (δC 163.5 ppm) and two methylenes (δC 50.1 and 35.9 ppm) (Table 4).
Compared to 1, compound 2 displayed similar COSY and HMBC correlations from the two methylene
protons resulting in the assignment of a taurine moiety. A 1,2-disubstituted benzene ring was deduced
on the basis of J coupling constants and COSY correlations of H-5 (δH 8.08, d, 7.8 Hz),
H-6 (δH 7.71, t, 7.2, 7.8 Hz), H-7 (δH 7.87, t, 7.2, 7.8 Hz) and H-8 (δH 8.06, d, 7.8 Hz). Two doublet
aromatic protons H-3 (δH 8.15 ppm) and H-4 (δH 8.55 ppm) coupling together with a J coupling value
of 8.4 Hz showed HMBC correlations from H-3 to C-4a (δC 129.2 ppm) and from H-4 to
C-5 (δC 128.7 ppm) and C-8a (δC 146.0 ppm) facilitating a connection from c to b at C-4.
Two quaternary carbons C-2 (δC 150.1 ppm) and C-8a (δC 146.0 ppm) were linked through a nitrogen atom
N-1 based on their downfield resonances, which are characteristic for the imine carbons [27]. According
to a HMBC correlation from H-4 to the imine C-2, C-2 was attached to C-3 leading to the establishment
of a quinoline ring system.
a
Table 4. NMR data for 2 in DMSO-d6 .
Position
δC
δH (J in Hz)
gCOSY
gHMBCAD
2
3
150.1
118.6
137.8
129.2
128.7
128.0
130.4
128.1
146.0
163.5
8.15, d (8.4)
8.55, d (8.4)
4
3
4a
4
2, 5, 8a
4a
5
8.08, d (7.8)
7.71, t (7.2, 7.8)
7.87, t (7.2, 7.8)
8.06, d (7.8)
6
4, 7, 8a
4a, 8
6
5, 7
6, 8
7
7
5, 8a
8
4a, 6
8a
9
10
11
12
9.29, t (5.4)
3.65, dd (5.4, 6.6)
2.72, t (6.6)
11
10, 12
11
35.9
50.1
9, 12
11
a
1H NMR at 600 MHz referenced to residual DMSO solvent (δH 2.50 ppm) and 13C NMR at 150 MHz
referenced to residual DMSO solvent (δC 39.52 ppm).
Due to lack of HMBC correlations from H-3 (δH 8.15 ppm) to C-9 (δC 163.5 ppm) or from H-10
(δH 9.29 ppm) to C-2 to obtain unequivocal evidence of the final structure, total synthesis of 2 was
undertaken to verify the structure assignment (Scheme 2). o-Nitrobenzaldehyde (7) was reduced with
4.5 equivalents (eq.) of iron powder in the presence of 0.05 mol of HCl (aqueous, aq.) in ethanol (EtOH)
under reflux in 40 min. Methyl pyruvate and potassium hydroxide powder were then added and the
condensation reaction was under reflux in additional 1.5 h to obtain quinoline-2-carboxylic acid (8)
(55% yield) [28]. This compound was coupled with taurine using EDCI/HOBt in DMF at rt for 48 h to

Mar. Drugs 2015, 13
4563
produce 2 with a yield of 75%. The NMR data of the synthetic compound 2 (Table 3) was identical to
that of the natural product 2 confirming the structure assignment of 2 as a new taurine amide. Thus, the
structure of 2, stolonine B, was established.
CHO
a (i and ii)
b
H
N
OH
NO2
N
SO3H
N
O
O
7
8
2
Scheme 2. Synthesis of 2. (a) (i) Fe, HCl, EtOH, reflux, 40 min; (ii) methyl pyruvate, KOH,
reflux, 1.5 h, 55% (b) Taurine, EDCI, HOBt, DMF, rt, 48 h, 75%.
Stolonine C (3) was isolated as a white amorphous solid. Its (−)-HRESIMS spectrum showed
a signal for [M − H]− at m/z 318.0550 indicating a molecular formula C14H13N3O4S to be assigned to
13
3. A C NMR spectrum combined with 2D NMR data indicated that compound 3 had 11 aromatic
carbons including six tertiary carbons (δC 132.2, 128.2, 122.3, 120.0, 113.9 and 112.3 ppm), five
quaternary carbons (δC 141.1, 139.6, 137.1, 128.7 and 121.0 ppm), one carbonyl (δC 164.3 ppm) and two
methylenes (δC 50.4 and 35.7 ppm) (Table 5). COSY and HMBC correlations confirmed 3 had a taurine
moiety (a, Figure 4) and a 1,2-disubstituted benzene ring (b, Figure 4), which were similar to those in 1
and 2. HMBC correlations from a singlet proton H-1 (δH 8.89 ppm) to C-3 (δC 139.6 ppm), C-4a
(δC 128.7 ppm) and C-9a (δC 137.1 ppm) and from a singlet proton H-4 (δH 8.84 ppm) to C-9a indicated
the presence of a 2,4,5-trisubstituted pyridine ring (c, Figure 4). HMBC correlations from an
exchangeable proton H-9 (δH 11.96 ppm) to C-4a, C-9a, C-4b (δC 121.0 ppm) and C-8a (δC 141.1 ppm)
supported the connection of b to c forming a β-carboline ring system. A HMBC key correlation
from H-4 to C-10 (δC 164.3 ppm) allowed the connection of c to a at C-3 (δC 139.6 ppm). Therefore, the
structure of stolonine C (3) was determined as shown in Figure 4.
Table 5. NMR data for 3 in DMSO-d6.
a
b,c
Position
δC
δH (J in Hz) a
δC
δH (J in Hz) b
gCOSY b gHMBCAD b
1
3
132.2
139.6
113.9
128.7
121.0
122.3
120.0
128.2
112.3
141.1
8.89, s
131.3
138.0
114.0
128.9
120.7
122.3
120.3
129.2
112.5
141.6
8.95, s
3, 4a, 9a
4
8.84, s
8.93, s
4b, 9a, 10
4a
4b
5
8.39, d (8.1)
7.30, t (7.2, 8.1)
7.59, t (7.2, 8.1)
7.65, d (8.1)
8.39, d (7.8)
7.35, t (7.2, 7.8)
7.64, t (7.2, 7.8)
7.70, d (7.8)
6
4a, 7, 8a
4b, 8
6
5, 7
6, 8
7
7
5, 8a
8
4b, 6
8a
9
11.96, s
12.11, s
4a, 4b, 8a, 9a
9a
10
137.1
164.3
136.7
163.3

Mar. Drugs 2015, 13
4564
Table 5. Cont.
a
b,c
Position
δC
δH (J in Hz) a
9.09, t (5.4)
δC
δH (J in Hz) b
gCOSY b gHMBCAD b
11
12
13
9.15, t (5.4)
3.66, dd (5.4, 6.6)
2.72, t (6.6)
12
35.7
50.4
3.64, dd (5.4, 6.3)
2.70, t (6.3)
35.9
50.3
11, 13
12
10, 13
12
a
1H NMR at 900 MHz at 25 °C referenced to residual DMSO solvent (δH 2.50 ppm) and 13C NMR at
225 MHz at 25 °C referenced to residual DMSO solvent (δC 39.52 ppm); b 1H NMR at 600 MHz at 30 °C
referenced to residual DMSO solvent (δH 2.50 ppm) and 13C NMR at 150 MHz at 30 °C referenced to residual
DMSO solvent (δC 39.52 ppm); c 13C chemical shifts obtained from correlations observed in gHSQCAD and
gHMBCAD spectra.
O
12
5
4
3
SO3H
4a
4b
6
7
N
H
11
10
13
N
HMBC
9a
a
N
H
9
8a
1
8
b
c
Figure 4. Partial structures (a, b and c) of 3 and their key HMBC correlations.
Total synthesis of 3 was performed using L-tryptophan methyl ester (9) as a starting material
(Scheme 3). The L-tryptophan methyl ester was treated with formaldehyde (37% aqueous) in a mixture
of MeOH and HCl 0.1 N (ratio 10:1) at rt for 16 h to give methyl (3S)-1,2,3,4-tetrahydro-β-carboline-3-
carboxylate [29]. The crude methyl (3S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylate was further
oxidized by activated manganese (IV) oxide (MnO2) in benzene (C6H6) under reflux for 5 h yielding a
crude methyl β-carboline-3-carboxylate [30]. This ester was then hydrolysed in a mixture of aq. NaOH
20% and MeOH (ratio 1:4) to provide β-carboline-3-carboxylic acid (10) (10% yield in three steps) [30].
Amide coupling of 10 and taurine was performed using EDCI/HOBt in DMF at rt in 16 h to produce 3
1
with a yield of 40%. The synthetic product 3 had superimposable H and 13C NMR data with
stolonine C (3) confirming its structure assignment (Table 3).
O
O
O
OH
a (i, ii and iii)
b
3
NH2
N
N
N
H
H
10
9
Scheme 3. Synthesis of 3. (a) (i) HCHO, MeOH, HCl 0.1 N, rt, 16 h; (ii) MnO2, C6H6, reflux,
5 h; (iii) NaOH 20%, MeOH, reflux, 45 min (10% in three steps); (b) Taurine, EDCI, HOBt,
DMF, rt, 16 h, 40%.
Biosynthesis of stolonines A–C (1–3) is shown in Scheme 4. Tryptophan (11) has been known as a
precursor of 3-indoleglyoxylic acid (6), quinoline-2-carboxylic acid (8) and β-carboline-3-carboxylic
acid (10) [31]. The acids 6, 8 and 10 undergo amide bond formation with taurine either by non-ribosomal
peptide synthase [32,33] or by acyl-CoA:amino acid N-acyltransferase 1 [34,35] to produce stolonines
A–C (1–3).

Mar. Drugs 2015, 13
4565
O
OH
O
OH
OH
OH
b
c
d
OH
e
f
1
O
O
O
O
O
N
N
N
N
N
H
H
13
H
14
OH
H
H
15
6
12
a
O
O
NH2
O
NH2
OH
OH
j
g
i
OH
h
f
2
NH2
OH
OH
O
O
O
N
N
N
N
H
NH2
H
O
O
11
17
8
16
18
k
O
O
OH
b and e
f
OH
3
NH
OH
N
N
H
N
H
10
O
19
Scheme 4. Biosynthesis of stolonines A–C (1–3). a: transaminase; b: decarboxylase; c: aldehyde dehydrogenase; d: hydroxylase; e: dehydrogenase;
f: taurine + non-ribosomal peptide synthase or acyl-CoA:amino acid N-acyltransferase 1; g: tryptophan 2,3-dioxygenase or indoleamine
2,3-dioxygenase; h: kynurenine formamidase or arylformamidase; i: kynurenine aminotransferases; j: reductase; k: glyoxylic acid.

Mar. Drugs 2015, 13
4566
The two known compounds, 11-hydroxyascididemin (4) and cnemidine A (5), were identified by
NMR comparisons with those in the literature [11].
Cytotoxic evaluation of compounds 1–3 against PC3 cells using the Alamar blue assay indicated that
these compounds inhibited the growth of PC3 cells at only 19%, 14%, and 26%, respectively,
at their maximum tested concentration of 20 μM. In order to explore whether these compounds have any
effect on cellular organelles in PC3 cells, an immunofluorescence assay with three markers for cell
membrane, nuclei, and mitochondria was performed. A high-content imaging system was used to image
and analyze the data. Compared to vehicle, compounds 1 and 3 had effects on cell morphology, nuclei
and mitochondria while compound 2 showed no or very weak effects (Figure 5A). In general, the
influence of 1 and 3 on PC3 cells was similar and clearly observed in cell morphology, nuclear, and
mitochondrial intensities as well as mitochondrial texture in a dose-dependent manner. In particular,
cells treated with 1 and 3 increased cell size and induced cells to become longer shown by the increase
in cell, mitochondrial and nuclear area, and the decrease in cell roundness. Compounds 1 and 3 also
caused mitochondrial texture to become larger and elongated compared to 2 and DMSO. The increase
in nuclear and mitochondrial intensities, which displayed brighter blue-whitish and brighter red-whitish
fluorescent appearance respectively in the images (Figure 5B), indicated that the nuclei and mitochondria
had more packed masses [36]. The brighter blue-whitish also demonstrated the condensation of
chromatins [37], which has been considered as a hallmark feature of apoptotic pathway of programmed
cell death [38,39]. The phenotype of nuclei suggested that compounds 1 and 3 affected the PC3 cell
death via apoptosis. Moreover, at the non-toxic doses, compounds 1 and 3 also increased the cell size
and induced mitochondrial texture elongation. How these compounds influence the PC3 cell morphology
and mitochondria is something that warrants further investigation.
Mitochondrial Area
Mitochondrial
Intensity
Mitochondrial
Texture
Nuclear Roundness
Nuclear Area
Nuclear Intensity
Cell Roundness
Cell Area
-10
0
10 20 30
-10
0
10 20 30
-10
0
10 20 30
%
%
%
20 μM 6.5 μM 2 μM
20 μM 6.5 μM 2 μM
20 μM 6.5 μM 2 μM
Stolonine A (1)
Stolonine B (2)
(A)
Stolonine C (3)
Figure 5. Cont.

Mar. Drugs 2015, 13
4567
Hoechst
MitoTracker
CellMask
Merged
Stolonine A
Stolonine B
Stolonine C
DMSO
(B)
Figure 5. (A) Phenotypic profiles for cell proliferation study of 1–3 (results were normalized
by a vehicle DMSO); (B) Representative images of the PC3 cells treated with 20 μM of
1–3 and DMSO in three channels: Hoechst 33,342 (Blue), MitoTracker (Red) and CellMask
(Yellow) (scale bar: 50 μm); chromatin condensation (white arrow), mitochondrial texture
elongation (green arrow) and larger cell size (cyan arrow) compared with vehicle DMSO.
3. Experimental Section
3.1. General Experimental Procedures
UV spectra were recorded on a CAMSPEC M501 UV/V is spectrophotometer. NMR spectra were
recorded at 30 °C on Varian Inova 500 and 600 MHz and on Bruker 900 MHz spectrometers. The 1H
13
and C chemical shifts were referenced to the DMSO-d6 solvent peaks at δH 2.50 and δC 39.52 ppm.
Standard parameters were used for the 2D NMR spectra obtained, which included gCOSY, gHSQCAD
(1JCH = 140 Hz), gHMBCAD (nJCH = 8 Hz), and ROESY. Low-resolution mass spectra were acquired
using a Mariner TOF mass spectrometer (Applied Biosystems Pty Ltd, Melbourne, Australia.).
High-resolution mass measurement was acquired on a Bruker Solarix 12 Tesla Fourier transform mass
spectrometer, fitted with an Apollo API source. For the HPLC isolation, a Water 600 pump equipped

Mar. Drugs 2015, 13
4568
with a Water 966 PDA detector and Gilson 715 liquid handler were used. A Betasil C18 column
(5 μm, 21.2 × 150 mm) and Hypersil BDS C18 column (5 μm, 10 × 250 mm) were used for
semi-preparative HPLC. A Phenomenex Luna C18 column (3 μm, 4.6 × 50 mm) was used for LC-MS
controlled by MassLynx 4.1 software (Waters, Milford, MA, USA). All solvents used for extraction
and chromatography were HPLC grade from RCI Labscan or Burdick & Jackson (Lomb Scientific,
Sydney, Australia), and the H2O used was ultrapure water (Arium® proVF, Sartorius Stedim Biotech,
Melbourne, Australia).
3.2. Animal Material
A specimen of the tunicate C. stolonifera (phylum Tunicata, class Ascidiacea, order Stolidobranchia,
family Styelidae) was collected at the depth of 15 m, at Peel Island, Myora Light, North Stradbroke
Island, Queensland, Australia in 2005. A voucher specimen (G322208) has been stored at the
Queensland Museum, South Brisbane, Queensland, Australia. Material was collected under Moreton
Bay Marine Park Permit Number QS2005/CVL588 and Queensland Fisheries Service General Fisheries
Permit Number PRM02988B issued to the Queensland Museum.
3.3. Extraction and Isolation
The freeze-dried and ground tunicate C. stolonifera (19 g) was extracted exhaustively with hexane
(250 mL), DCM (250 mL) and MeOH (2 × 250 mL), respectively. The DCM and MeOH extracts were
combined and the solvents were evaporated to yield a yellow residue (2.2 g). This extract was
pre-adsorbed onto C18 (1 g) and packed dry into a small cartridge, which was connected to a C18
preparative HPLC column (5 μm, 21.2 × 150 mm). A linear gradient from 100% H2O (0.1% TFA)
to 100% MeOH (0.1% TFA) was performed over 60 min at a flow rate of 9 mL/min and 60 fractions
(1.0 min each) were collected. Pure cnemidine A (5, 3.5 mg, 0.018% dry wt) and 11-hydroxyascididemin
(4, 4.1 mg, 0.021% dry wt) were obtained in fractions 28, 29 and 32 respectively. Fraction 19 was further
chromatographed on a Hypersil C18 HPLC column (5 μm, 10 × 250 mm) from 10% MeOH (0.1%
TFA)/90% H2O (0.1% TFA) to 25% MeOH (0.1% TFA)/75% H2O (0.1% TFA) at a flow rate of
4 mL/min in 30 min to yield stolonine C (3, 0.1 mg, 0.0021% dry wt) in fraction 14 and stolonine A
(1, 0.9 mg, 0.0047% dry wt) in fractions 17–18. Fractions 20 and 21 in the first chromatography were
combined and purified using the Hypersil C18 HPLC column (5 μm, 10 × 250 mm) from 10% MeOH
(0.1% TFA)/90% H2O (0.1% TFA) to 40% MeOH (0.1% TFA)/60% H2O (0.1% TFA) at a flow rate of
4 mL/min in 45 min to obtain stolonine C (3, 0.3 mg, 0.0021% dry wt in total) in fraction 33 and
stolonine B (2, 1.2 mg, 0.0063% dry wt) in fractions 34–36.
Stolonine A (1): white, amorphous solid; UV (MeOH) λmax (log ε) 210 (3.8), 252 (3.5) and
325 (3.3) nm; IR (film) νmax 3307, 1681, 1205, 1049 and 802 cm−1; 1H (600 MHz, DMSO-d6) and 13C
(150 MHz, DMSO-d6) NMR data are summarized in Table 1; (−)-HRESIMS m/z 295.0390 [M − H]−
(calcd for [C12H11N2O5S]−, 295.0394, Δ −1.4 ppm).
Stolonine B (2): white, amorphous solid; UV (MeOH) λmax (log ε) 210 (3.8) and 240 (3.9) nm;
1
IR (film) νmax 3386, 1684, 1204 and 1066 cm−1; H (600 MHz, DMSO-d6) and 13C (150 MHz,

Mar. Drugs 2015, 13
4569
DMSO-d6) NMR data are summarized in Table 3; (−)-HRESIMS m/z 279.0441 [M − H]− (calcd for
[C12H11N2O4S]−, 279.0445, Δ −1.4 ppm).
Stolonine C (3): white, amorphous solid; UV (MeOH) λmax (log ε) 210 (4.1) and 272 (3.8) nm; IR
(film) νmax 3418, 1682, 1197 and 1034 cm−1; 1H (600 MHz, DMSO-d6) and 13C (150 MHz, DMSO-d6)
NMR data are summarized in Table 4; (−)-HRESIMS m/z 318.0550 [M − H]− (calcd for [C14H12N3O4S]−,
318.0554, Δ −1.3 ppm).
Synthetic stolonine A (1): To a solution of taurine (12 mg, 0.096 mmol) in dry DMF (1 mL) was
added HOBt (26 mg, 0.193 mmol) and the reaction mixture was stirred for 15 min at rt. The reaction
mixture was then cooled to 0 °C, EDCI (37 mg, 0.193 mmol) was added and continued stirring for
30 min at 0 °C. To this mixture was then added 3-indoleglyoxylic acid (6, 18 mg, 0.095 mmol) and
the mixture was stirred for 21 h at rt. The crude product was concentrated in vacuo and separated by
RP-HPLC (MeOH, H2O, 0.1% TFA) to obtain the synthetic stolonine A (18 mg, 64%); IR (film)
1
νmax 3371, 1681, 1205, 1047, 802 and 749 cm−1; H (600 MHz, DMSO-d6) and 13C (150 MHz,
DMSO-d6) NMR data are summarized in Table 5; (−)-HRESIMS m/z 295.0391 [M − H]− (calcd for
[C12H11N2O5S]−, 295.0394, Δ −1.0 ppm).
Quinoline-2-carboxylic acid (8): To a solution of o-nitrobenzaldehyde (7, 302 mg, 2 mmol) in ethanol
(5 mL) was added iron powder (504 mg, 9 mmol), followed by 0.1 N HCl (2 mL, 0.2 mmol) and the
resulting mixture was vigorously stirred under reflux for 45 min. Methyl pyruvate (200 μL, 2 mmol) and
powder KOH (135 mg, 2.4 mmol) were added slowly. The reaction mixture was stirred under reflux for
90 min and then cooled to rt. The crude product was purified by RP-HPLC (MeOH, H2O, 0.1% TFA) to
1
yield 8 (190 mg, 55% in two steps); H NMR (500 MHz, DMSO-d6) δ 8.56 (1H, d, J = 8.5 Hz),
8.16 (1H, d, J = 8.0 Hz), 8.11 (1H, d, J = 8.5 Hz), 8.09 (1H, d, J = 8.0 Hz), 7.88 (1H, t, J = 8.0 and 7.5 Hz)
and 7.74 (1H, t, J = 8.0 and 7.5 Hz); 13C NMR (125 MHz, DMSO-d6) δ 166.2 (COOH), 148.5 (C), 146.6
(C), 137.6 (CH), 130.5 (CH), 129.5 (CH), 128.7 (C), 128.5 (CH), 127.9 (CH) and 120.6 (CH).
(+)-LRESIMS m/z 174.
Synthetic stolonine B (2): To a solution of taurine (13 mg, 0.104 mmol) in dry DMF (1 mL) was
added HOBt (28 mg, 0.207 mmol) and the reaction mixture was stirred for 15 min at rt. The reaction
mixture was then cooled to 0 °C, EDCI (40 mg, 0.209 mmol) was added and continued stirring for
30 min at 0 °C. To this mixture was then added compound 8 (18 mg, 0.104 mmol) and the mixture was
stirred for 48 h at rt. The pure synthetic stolonine B was purified by RP-HPLC (MeOH, H2O, 0.1% TFA)
1
to obtain 21.8 mg (75% yield); IR (film) νmax 3383, 1677, 1201 and 1064 cm−1; H (600 MHz,
DMSO-d6) and 13C (150 MHz, DMSO-d6) NMR data are summarized in Table 5; (−)-HRESIMS
m/z 279.0446 [M − H]− (calcd for [C12H11N2O4S]−, 279.0445, Δ 0.4 ppm).
β-carboline-3-carboxylic acid (10): Formaldehyde (37%, 2 mL) was added to L-tryptophan methyl
ester hydrochloride (9) (2.54 g, 10 mmol) in aqueous MeOH (10 mL, MeOH-H2O (10:1)). The resulting
mixture was stirred at rt for 16 h. The reaction mixture was evaporated to dryness in vacuo and oxidized
by activated MnO2 (2.5 g, 28.7 mmol) in benzene under reflux for 5 h. The hot solution was filtered
through a bed of C18 to remove the MnO2 and the filter cake was washed with hot benzene. The crude
product was suspended in a mixture of aq. NaOH 20% and MeOH (ratio 1:4) and heated to reflux for
45 min. The reaction was cooled to rt, evaporated to dryness in vacuo and then loaded onto RP-HPLC
1
(MeOH, H2O, 0.1% TFA) yielding 10 (215 mg, 10% in three steps). H NMR (600 MHz, DMSO-d6)

Mar. Drugs 2015, 13
4570
δ 12.07 (1H, s), 8.98 (1H, s), 8.92 (1H, s), 8.39 (1H, d, J = 8.4 Hz), 7.67 (1H, d, J = 8.4 Hz),
13
7.60 (1H, t, J = 7.2, 7.8 Hz), 7.31 (1H, t, J = 7.2, 7.8 Hz); C NMR (150 MHz, DMSO-d6) δ 166.8
(COOH), 141.1 (C), 137.4 (2xC), 133.1 (CH), 128.7 (CH), 127.8 (C), 122.2 (CH), 120.9 (C),
120.1 (CH), 117.2 (CH), 112.3 (CH). (+)-LRESIMS m/z 213.
Synthetic stolonine C (3): To a solution of taurine (5 mg, 0.040 mmol) in dry DMF (1 mL) was added
HOBt (13.5 mg, 0.1 mmol) and the reaction mixture was stirred for 15 min at rt. The reaction mixture
was then cooled to 0 °C, EDCI (19 mg, 0.099 mmol) was added and continued stirring for
30 min at 0 °C. To this mixture was then added 10 (8 mg, 0.038 mmol) and the mixture was stirred for
16 h at rt. The crude product was concentrated in vacuo and separated by RP-HPLC (MeOH, H2O, 0.1%
TFA) to obtain the synthetic stolonine C (4.8 mg, 40%); IR (film) νmax 3419, 1683, 1198 and 1034 cm−1;
1H (600 MHz, DMSO-d6) and 13C (150 MHz, DMSO-d6) NMR data are summarized in Table 5;
(−)-HRESIMS m/z 318.0556 [M − H]− (calcd for [C14H12N3O4S]−, 318.0554, Δ 0.6 ppm).
3.4. Computational Details
Molecular mechanics calculations were performed using Macromodel [40] interfaced to the Maestro
program [41]. All conformational searches used the MMFFs force field. Twenty-one conformers of 1-I
and six conformers of 1-II within a relative energy of 2 kcal/mol were found. The geometries of these
conformers were subsequently optimized at DFT level with the B3LYP functional and 6-31G(d) basis
set using Jaguar [42]. Single point calculations in DMSO with the mPW1PW91 functional and the same
basis set were employed using Jaguar [42] to provide the shielding constant of carbon and proton nuclei.
1
13
Meanwhile, the same procedure was applied on tetramethylsilane (TMS). Final H and C chemical
shifts were obtained as the results of the Boltzmann weighted average. The theoretical chemical shifts
were calculated according to a below equation.
δꢀꢃꢁꢂꢀ ꢄ σꢅꢆꢇ ꢈ σꢃ
(1)
where δꢀꢃꢁꢂꢀ is the calculated shift for nucleus x (in ppm); σꢃ is the shielding constant for nucleus x;
σꢅꢆꢇ is the shielding constant for the carbon in TMS σꢅꢆꢇ = 194.6867 ppm and for the proton in TMS
σꢅꢆꢇ = 32.0845 ppm.
Statistical parameters were used to quantify the agreement between experimental and calculated data:
-
The slope (a), the intercept (b) and the correlation coefficient (R2) were determined from a plot
of δꢀꢁꢂꢀ against δꢉꢃꢊ for each particular compound.
-
Systematic errors during the shift calculation were removed by empirical scaling according to
δꢋꢀꢁꢂꢉꢌ ꢄ ꢍδꢀꢁꢂꢀ ꢈ ꢎꢏ/ꢐ
The corrected mean absolute error (CMAE) was defined as ꢔꢕꢖꢑδꢋꢀꢁꢂꢉꢌ ꢈ δꢉꢃꢊꢑ/ꢒ
ꢓ
∑
-
-
DP4 parameter was calculated by using the online applet [43].
3.5. Cytotoxicity Assay
Human prostate adenocarcinoma cells (PC3) and human neonatal foreskin fibroblast (noncancer cells,
NFF) were grown in media RPMI-1640 (Life Technologies, Grand Island, NY, USA) supplemented with
10% foetal bovine serum (FBS) (Life Technologies, Grand Island, NY, USA). Cells were grown under
5% CO2 in a humidified environment at 37 °C. Fifty microliters of media containing 500 cells were

Mar. Drugs 2015, 13
4571
added to a 384 well microtiter plate (Perkin Elmer, Shelton, CT, USA, part number: 6,007,660)
containing 0.2 μL of a compound. Final compound concentrations tested were 20, 6.5, 2, 0.65, 0.2, 0.065,
0.020 and 0.0065 μM (final DMSO concentration of 0.4%). Each concentration in media was tested in
triplicate and in two independent experiments. Cells and compounds were then incubated in 72 h at
37 °C, 5% CO2 and 80% humidity. Cell proliferation was measured with the addition of 10 μL of a 60%
Alamar blue (Invitrogen, Carlsbad, CA, USA) solution in media to each well of the microtiter plate to
give a final concentration of 10% Alamar blue. The plates were incubated at 37 °C, 5% CO2 and 80%
humidity within 24 h. The fluorescence of each well was read at excitation 535 nm and emission
590 nm on the Perkin Elmer EnVision Multilabel Reader 2104. Eight-point concentration response curves
were then analyzed using non-linear regression and IC50 values determined by using GraphPad Prism 5
(GraphPad Software Inc., La Jolla, CA, USA). Paclitaxel and doxorubicin were used during each
screening as positive control compounds.
3.6. Immunofluorescence Staining
Cells (2000 cells/well) were allowed to seed in a 96-well plate (CellCarrier, Perkin Elmer, Shelton,
CT, USA, part number: 6,005,558) containing 0.4 μL of a compound at room temperature for 30 min
and then placed under 5% CO2 in a humidified environment at 37 °C. After 72 h incubation, 100 μL of
a solution containing 1/1000 Hoechst 33,342 (Molecular Probes, Invitrogen, Carlsbad, CA, USA),
1 μM MitoTracker Deep Red (Molecular Probes, Invitrogen, Carlsbad, CA, USA) and 1/1000 CellMask
Plasma Membrane (Molecular Probes, Invitrogen, Carlsbad, CA, USA) were added to each well and
incubated for 30 min at 37 °C. Stained cells were washed once with PBS to remove excess stains and
then replaced with 100 μL of PBS before being imaged.
3.7. Automated Microscopy and Image Analysis
Plates were imaged with an Operetta high-content wide-field fluorescence imaging system, coupled
to Harmony software (Perkin Elmer, Shelton, CT, USA). Wells in a 96-well plate were captured at
25 locations per well at 20× magnification at three wavelengths (350 nm: Hoechst 33,342; 554 nm:
CellMask Plasma Membrane; 644 nm: MitoTracker Deep Red). The three images were combined and
analyzed using the Harmony software. The analysis protocol involved in the following steps: (1) each
cell nucleus was identified using Hoechst stain; (2) the cell cytoplasm as defined from CellMask
fluorescence; (3) cells that overlapped the border of the image were excluded from the analysis.
Each concentration was repeated in at least two separated experiments. To obviate observer bias, the
image analysis was automated using the same parameters for every image.
4. Conclusions
Contributing to the chemical study on the underexplored marine tunicate Cnemidocarpa stolonifera,
three new alkaloids stolonines A–C (1–3) belonging to the taurine amide structure class were identified.
Structures of these compounds were determined by NMR spectroscopy and confirmed by synthetic
methods. Stolonines A–C (1–3) represent the 48–50th naturally occurring taurine amide compounds.
However, this is the first time that the conjugates of taurine with 3-indoleglyoxylic acid,

Mar. Drugs 2015, 13
4572
quinoline-2-carboxylic acid and β-carboline-3-carboxylic acid have been reported. Although compounds
1–3 displayed no cytotoxicity against the prostate cancer PC3 cells at the concentration of 20 μM,
an immunofluorescence assay on PC3 cells revealed that compounds 1 and 3 increased cell size, induced
mitochondrial texture elongation and affected the PC3 cell death via apoptotic pathway. Further
investigation would be necessary to understand their mechanism of action on PC3 cells.
Supplementary Materials
IR, 1D and 2D NMR spectra of stolonines A–C (1–3) and other synthetic compounds (8 and 10);
and calculated 13C and 1H NMR chemical shifts for each conformer of compounds 1-I and 1-II.
Acknowledgments
One of the authors (T.D.T.) acknowledges Griffith University for the provision of the “Griffith
University International Postgraduate Research Scholarship and Griffith University Postgraduate
Research Scholarship”. We thank H. T. Vu at Eskitis Institute, Griffith University for acquiring the
HRESIMS measurement and G. Pierens at Center for Advanced Imaging, University of Queensland for
acquiring the 900 MHz NMR measurement. We acknowledge the Australian Research Council for
support toward NMR and MS equipment (ARC LE0668477 and ARC LE0237908) and funding
(ARC Discovery DP130102400).
Author Contributions
Ronald J. Quinn conceived and designed the research. Ronald J. Quinn and Ngoc B. Pham supervised
the chemical experiments, structure elucidation, DFT calculations, synthesis and biological experiments.
Trong D. Tran performed the natural product isolation, structural identification, DFT calculations,
synthesis, cytotoxicity assays, immunofluorescence staining and cell imaging. John N. A. Hooper and
Merrick Ekins collected and identified the tunicate samples. Trong D. Tran, Ngoc B. Pham and Ronald
J. Quinn interpreted the results and wrote the manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Dias, D.A.; Urban, S.; Roessner, U. A historical overview of natural products in drug discovery.
Metabolites 2012, 2, 303–336.
2. Bergmann, W.; Feeney, R.J. The isolation of a new thymine pentoside from sponges. J. Am. Chem.
Soc. 1950, 72, 2809–2810.
3. Bergmann, W.; Feeney, R.J. Contributions to the study of marine products. XXXII. The nucleosides
of sponges. I. J. Org. Chem. 1951, 16, 981–987.
4. Hu, G.P.; Yuan, J.; Sun, L.; She, Z.G.; Wu, J.H.; Lan, X.J.; Zhu, X.; Lin, Y.C.; Chen, S.P. Statistical
research on marine natural products based on data obtained between 1985 and 2008. Mar. Drugs
2011, 9, 514–525.

Mar. Drugs 2015, 13
4573
5. Mehbub, M.F.; Lei, J.; Franco, C.; Zhang, W. Marine sponge derived natural products between
2001 and 2010: Trends and opportunities for discovery of bioactives. Mar. Drugs 2014, 12,
4539–4577.
6. Leal, M.C.; Puga, J.; Serodio, J.; Gomes, N.C.M.; Calado, R. Trends in the discovery of new marine
natural products from invertebrates over the last two decades—Where and what are we
bioprospecting? PLoS ONE 2012, 7, e30580.
7. Camp, D.; Newman, S.; Pham, N.B.; Quinn, R.J. Nature bank and the queensland compound library:
Unique international resources at the eskitis institute for drug discovery. Comb. Chem. High
Throughput Screen. 2014, 17, 201–209.
8. Quinn, R.J.; Carroll, A.R.; Pham, N.B.; Baron, P.; Palframan, M.E.; Suraweera, L.; Pierens, G.K.;
Muresan, S. Developing a drug-like natural product library. J. Nat. Prod. 2008, 71, 464–468.
9. Tran, T.D.; Pham, N.B.; Fechner, G.; Quinn, R.J. Chemical investigation of drug-like compounds
from the australian tree, Neolitsea dealbata. Bioorg. Med. Chem. Lett. 2010, 20, 5859–5863.
10. Camp, D.; Davis, R.A.; Campitelli, M.; Ebdon, J.; Quinn, R.J. Drug-like properties: Guiding
principles for the design of natural product libraries. J. Nat. Prod. 2012, 75, 72–81.
11. Tran, T.D.; Pham, N.B.; Quinn, R.J. Structure determination of pentacyclic pyridoacridine alkaloids
from the australian marine organisms Ancorina geodides and Cnemidocarpa stolonifera. Eur. J.
Org. Chem. 2014, 2014, 4805–4816.
12. Bittner, S.; Win, T.; Gupta, R. Gamma-L-glutamyltaurine. Amino Acids 2005, 28, 343–356.
13. Chung, M.C.; Malatesta, P.; Bosquesi, P.L.; Yamasaki, P.R.; Santos, J.L.D.; Vizioli, E.O. Advances
in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS
diseases. Pharmaceuticals 2012, 5, 1128–1146.
14. Carbone, M.; Núñez-Pons, L.; Ciavatta, M.L.; Castelluccio, F.; Avila, C.; Gavagnin, M. Occurrence
of a taurine derivative in an Antarctic glass sponge. Nat. Prod. Commun. 2014, 9, 469–470.
15. Dictionary of Natural Products 23.2 Online; Taylor & Francis Group: FL, USA: 2015.
16. Pretsch, E.; Buhlmann, P.; Badertscher, M. Structure Determination of Organic Compounds;
Springer, Berlin, Germany: 2009.
17. Hosoya, T.; Hirokawa, T.; Takagi, M.; Shin-ya, K. Trichostatin analogues JBIR-109, JBIR-110,
and JBIR-111 from the marine sponge-derived Streptomyces sp. RM72. J. Nat. Prod. 2012, 75,
285–289.
18. Gupta, P.; Sharma, U.; Schulz, T.C.; McLean, A.B.; Robins, A.J.; West, L.M. Bicyclic C21
terpenoids from the marine sponge Clathria compressa. J. Nat. Prod. 2012, 75, 1223–1227.
19. Bi, D.; Chai, X.Y.; Song, Y.L.; Lei, Y.; Tu, P.F. Novel bile acids from bear bile powder and bile of
geese. Chem. Pharm. Bull. 2009, 57, 528–531.
20. Smith, S.G.; Goodman, J.M. Assigning stereochemistry to single diastereoisomers by GIAO NMR
calculation: The DP4 probability. J. Am. Chem. Soc. 2010, 132, 12946–12959.
21. Micco, S.D.; Zampella, A.; D’Auria, M.V.; Festa, C.; Marino, S.D.; Riccio, R.; Butts, C.P.;
Bifulco, G. Plakilactones G and H from a marine sponge. Stereochemical determination of highly
flexible systems by quantitative NMR-derived interproton distances combined with quantum
mechanical calculations of 13C chemical shifts. Beilstein J. Org. Chem. 2013, 9, 2940–2949.

Mar. Drugs 2015, 13
4574
22. Brown, S.G.; Jansma, M.J.; Hoye, T.R. Case study of empirical and computational chemical shift
analyses: Reassignment of the relative configuration of phomopsichalasin to that of diaporthichalasin.
J. Nat. Prod. 2012, 75, 1326–1331.
23. Wyche, T.P.; Hou, Y.; Rivera, E.V.; Braun, D.; Bugni, T.S. Peptidolipins B–F, antibacterial
lipopeptides from an ascidian-derived Nocardia sp. J. Nat. Prod. 2012, 75, 735–740.
24. Wyche, T.P.; Hou, Y.; Braun, D.; Cohen, H.C.; Xiong, M.P.; Bugni, T.S. First natural analogs of
the cytotoxic thiodepsipeptide thiocoraline A from a marine Verrucosispora sp. J. Org. Chem. 2011,
76, 6542–6547.
25. Paterson, I.; Dalby, S.M.; Roberts, J.C.; Naylor, G.J.; Guzman, E.A.; Isbrucker, R.; Pitts, T.P.;
Linley, P.; Divlianska, D.; Reed, J.K.; et al. Leiodermatolide, a potent antimitotic macrolide from
the marine sponge Leiodermatium sp. Angew. Chem. Int. Ed. 2011, 50, 3219–3223.
26. Ienaga, K.; Higashiura, K.; Toyomaki, Y.; Matsuura, H.; Kimura, H. Simple peptide. II. Syntheses
and properties of taurine dipeptides containing neutral α-amino acid. Chem. Pharm. Bull. 1988, 36,
70–77.
27. Silverstein, R.M.; Webster, F.X.; Kiemle, D. Spectrometric Identification of Organic Compounds,
7th ed.; John Wiley & Son: Danvers, MA, USA, 2005.
28. Li, A.H.; Ahmed, E.; Chen, X.; Cox, M.; Crew, A.P.; Dong, H.Q.; Jin, M.; Ma, L.; Panicker, B.;
Siu, K.W.; et al. A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes.
Org. Biomol. Chem. 2007, 5, 61–64.
29. Chaniyara, R.; Tala, S.; Chen, C.W.; Zang, X.; Kakadiya, R.; Lin, L.F.; Chen, C.H.; Chien, S.I.;
Chou, T.C.; Tsai, T.H.; et al. Novel antitumor indolizino[6,7-b]indoles with multiple modes
of action: DNA cross-linking and topoisomerase I and II inhibition. J. Med. Chem. 2013, 56,
1544–1563.
30. Yin, W.; Majumder, S.; Clayton, T.; Petrou, S.; VanLinn, M.L.; Namjoshi, O.A.; Ma, C.;
Cromer, B.A.; Roth, B.L.; Platt, D.M.; et al. Design, synthesis, and subtype selectivity of
3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward
agents for treatment of alcohol abuse. Bioorg. Med. Chem. 2010, 18, 7548–7564.
31. Dewick, P.M. Medicinal Natural Products: A Biosynthetic Approach, 3rd ed.; John Wiley & Sons:
Chichester, UK, 2009.
32. Felnagle, E.A.; Jackson, E.E.; Chan, Y.A.; Podevels, A.M.; Berti, A.D.; McMahon, M.D.;
Thomas, M.G. Nonribosomal peptide synthetases involved in the production of medically relevant
natural products. Mol. Pharm. 2008, 5, 191–211.
33. Strieker, M.; Tanovic, A.; Marahiel, M.A. Nonribosomal peptide synthetases: Structures and
dynamics. Curr. Opin. Struct. Biol. 2010, 20, 234–240.
34. Hunt, M.C.; Siponen, M.I.; Alexson, S.E.H. The emerging role of acyl-coa thioesterases and
acyltransferases in regulating peroxisomal lipid metabolism. Biochim. Biophys. Acta 2012, 1822,
1397–1410.
35. Farrell, E.K.; Merkler, D.J. Biosynthesis, degradation and pharmacological importance of the fatty
acid amides. Drug Discov. Today 2008, 13, 558–568.
36. Bottone, M.G.; Santin, G.; Aredia, F.; Bernocchi, G.; Scovassi, C.P.I. Morphological Features of
Organelles during Apoptosis: An Overview. Cells 2013, 2, 294–305.

Mar. Drugs 2015, 13
4575
37. Akter, R.; Hossain, M.Z.; Kleve, M.G.; Gealt, M.A. Wortmannin induces MCF-7 breast cancer cell
death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen
species, and membrane blebbing. Breast Cancer (Dove Med. Press) 2012, 4, 103–113.
38. Häcker, G. The morphology of apoptosis. Cell Tissue Res. 2000, 301, 5–17.
39. Eidet, J.R.; Pasovic, L.; Maria, R.; Jackson, C.J.; Utheim, T.P. Objective assessment of changes in
nuclear morphology and cell distribution following induction of apoptosis. Diagn. Pathol. 2014, 9,
doi:10.1186/1746-1596-9-92.
40. Schrödinger, LCC. MacroModel, Version 9.9; Schrödinger, LCC: New York, NY, USA, 2012.
41. Schrödinger, LCC. Maestro, Version 9.3.5; Schrödinger, LCC: New York, NY, USA, 2012.
42. Schrödinger, LCC. Jaguar, Version 8.0; Schrödinger, LCC: New York, NY, USA, 2012.
43. Assignment of stereochemistry and structure using NMR and DP4. Available online:
http://www-jmg.ch.cam.ac.uk/tools/nmr/DP4/ (accessed on 18 June 2014)
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).